FY2024 EPS Estimates for ATOS Increased by Cantor Fitzgerald

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for Atossa Therapeutics in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($0.20) per share for the year, up from their previous forecast of ($0.22). The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.21) per share.

Several other brokerages have also issued reports on ATOS. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Finally, HC Wainwright raised their price target on shares of Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Atossa Therapeutics Stock Performance

Shares of NASDAQ ATOS opened at $1.28 on Monday. The stock has a market cap of $161.03 million, a P/E ratio of -5.82 and a beta of 1.23. The firm has a 50 day moving average price of $1.44 and a two-hundred day moving average price of $1.37. Atossa Therapeutics has a 52-week low of $0.65 and a 52-week high of $2.31.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Atossa Therapeutics during the first quarter valued at approximately $72,000. Virtu Financial LLC bought a new stake in Atossa Therapeutics during the first quarter worth $151,000. Rhumbline Advisers purchased a new stake in Atossa Therapeutics in the 2nd quarter valued at $161,000. Finally, Vanguard Group Inc. lifted its stake in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after acquiring an additional 78,269 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.